JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Modified Glasgow Prognostic Score Incorporating CRP/Albumin Ratio and LDH Levels as Prognostic Indicators in Patients with Multiple Myeloma: A Retrospective Study

  • 0Department of Internal Medicine, Division of Hematology, Afyonkarahisar Health Sciences University, Afyonkarahisar, Türkiye.
Cancer Management and Research +

|

September 22, 2025

|

September 22, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Integrating CRP/Albumin Ratio (CAR) and Lactate Dehydrogenase (LDH) into the Modified Glasgow Prognostic Score (mGPS) improves prognostic accuracy for multiple myeloma (MM) patients. This enhanced scoring system aids in better risk stratification and clinical decision-making for MM.

Area Of Science

  • Hematology
  • Oncology
  • Biochemistry

Background

  • Multiple myeloma (MM) prognosis relies on accurate staging and risk stratification.
  • Existing prognostic scores may not fully capture the systemic inflammatory state in MM patients.
  • Biomarkers reflecting inflammation, such as CAR and LDH, are increasingly recognized for their clinical relevance.

Purpose Of The Study

  • To evaluate the prognostic value of integrating the C-reactive protein/albumin ratio (CAR) and lactate dehydrogenase (LDH) into the Modified Glasgow Prognostic Score (mGPS) for multiple myeloma (MM).
  • To determine if this combined approach enhances the accuracy of risk stratification compared to mGPS alone.

Main Methods

  • A retrospective analysis of 130 MM patients diagnosed between 2017 and 2023.
  • Collection of demographic, clinical, laboratory data (mGPS, CAR, LDH, ISS staging).
  • Survival outcomes assessed using Kaplan-Meier curves and Cox regression models.

Main Results

  • The International Staging System (ISS) score was the strongest mortality predictor.
  • Elevated LDH (> 250 IU) and CAR (> 0.51) were independent risk factors for mortality.
  • mGPS 2 combined with elevated LDH or CAR showed significantly poorer survival and progression-free survival (PFS).
  • mGPS, CAR, and LDH independently predicted disease progression.

Conclusions

  • Integrating CAR and LDH into the mGPS improves risk stratification for MM patients.
  • This enhanced model provides a cost-effective and accessible tool for assessing systemic inflammation and tumor burden.
  • The findings support the potential clinical utility of the enhanced mGPS in MM patient management.

Keywords: